Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rivaroxaban

FDA-approved product (tablet, oral), marketed as Rivaroxaban, Xarelto.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Rivaroxaban
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute coronary syndrome
  • Atrial fibrillation
  • Coronary artery disease
  • Deep vein thrombosis
  • Peripheral arterial disease
  • Pulmonary embolism
  • Recurrent thrombophlebitis
  • Stroke
  • Thrombotic disease
  • Total joint arthroplasty
  • Venous thromboembolism
  • Venous thrombosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Direct factor xa inhibitors
FDA pharmacologic class
Factor Xa Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA41.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli30.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae43.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Rivaroxaban in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rivaroxaban with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • REmotely Supervised Exercise Therapy Trial 2

    NCT04925219 · start 2021-06-01

    Registered record
    Registry ID
    NCT04925219
    Conditions
    Claudication, Intermittent; Peripheral Arterial Disease
    Interventions
    Remotely supervised exercise programme; Self-directed exercise
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-06-01
    Completion
    2024-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClaudication, Intermittent; Peripheral Arterial Disease
    InterventionRemotely supervised exercise programme; Self-directed exercise
    PhaseNot applicable
    Registry statusUnknown

  • Alexa, What is Eliquis and Xarelto?

    NCT04790773 · start 2021-05-21

    Registered record
    Registry ID
    NCT04790773
    Conditions
    Patient Engagement; Patient Satisfaction
    Interventions
    Amazon Alexa based voice recording patient education
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2021-05-21
    Completion
    2021-10-31
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPatient Engagement; Patient Satisfaction
    InterventionAmazon Alexa based voice recording patient education
    PhaseNot applicable
    Registry statusTerminated

  • C Reactive Protein in Home Quarantined Coronavirus Disease 2019 (COVID -19) Patients.

    NCT04935515 · start 2021-04-15

    Registered record
    Registry ID
    NCT04935515
    Conditions
    COVID -19
    Interventions
    Oral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins; Oral low dose steroid; Intravenous Antibiotics with Low dose steroid.; Oral anti-coagulant
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-04-15
    Completion
    2021-06-06
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID -19
    InterventionOral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins; Oral low dose steroid; Intravenous Antibiotics with Low dose steroid.; Oral anti-coagulant
    PhaseNot applicable
    Registry statusCompleted

  • Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels

    NCT04539301 · start 2021-04-01

    Registered record
    Registry ID
    NCT04539301
    Conditions
    Anticoagulation; Venous Thromboembolism; Atrial Fibrillation
    Interventions
    Estimated anticoagulant level (conversion factor x anti-Xa activity)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-04-01
    Completion
    2024-05-01
    Enrolment
    2,100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnticoagulation; Venous Thromboembolism; Atrial Fibrillation
    InterventionEstimated anticoagulant level (conversion factor x anti-Xa activity)
    PhaseNot recorded
    Registry statusUnknown

  • Bleeding Risk With Apixaban Versus Rivaroxaban in Acute Pulmonary Embolism

    NCT07774273 · start 2021-01-01

    Registered record
    Registry ID
    NCT07774273
    Conditions
    Pulmonary Embolism Acute; Venous Thromboembolism (VTE)
    Interventions
    Drug: Apixaban; Drug: Rivaroxaban
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-01-01
    Completion
    2026-02-15
    Enrolment
    540

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Embolism Acute; Venous Thromboembolism (VTE)
    InterventionDrug: Apixaban; Drug: Rivaroxaban
    PhaseNot applicable
    Registry statusCompleted

  • Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial

    NCT04394377 · start 2020-06-21

    Registered record
    Registry ID
    NCT04394377
    Conditions
    Coronavirus Infection
    Interventions
    Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed; Group 2: control group with enoxaparin 40mg/d
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-06-21
    Completion
    2021-05-30
    Enrolment
    615

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronavirus Infection
    InterventionGroup 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed; Group 2: control group with enoxaparin 40mg/d
    PhasePhase 4
    Registry statusCompleted

  • DUAL Pathway Inhibition to Improve Endothelial Function in Peripheral Artery Disease

    NCT04218656 · start 2020-06-08

    Registered record
    Registry ID
    NCT04218656
    Conditions
    Peripheral Artery Disease
    Interventions
    Rivaroxaban 2.5 Mg Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-06-08
    Completion
    2021-12-31
    Enrolment
    159

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral Artery Disease
    InterventionRivaroxaban 2.5 Mg Oral Tablet
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetics of Rivaroxaban After Bariatric Surgery

    NCT04180436 · start 2020-01-15

    Registered record
    Registry ID
    NCT04180436
    Conditions
    Bariatric Surgery; Morbid Obesity
    Interventions
    rivaroxaban 20 mg once daily 8 days
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-01-15
    Completion
    2022-06-27
    Enrolment
    67

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBariatric Surgery; Morbid Obesity
    Interventionrivaroxaban 20 mg once daily 8 days
    PhasePhase 1
    Registry statusCompleted

  • Rivaroxaban in Elderly NVAF Patients With or Without Renal Impairment

    NCT04096547 · start 2019-09-25

    Registered record
    Registry ID
    NCT04096547
    Conditions
    Atrial Fibrillation; Rivaroxaban; Elderly; Renal Insufficiency
    Interventions
    Rivaroxaban
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2019-09-25
    Completion
    2022-08-30
    Enrolment
    1,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Rivaroxaban; Elderly; Renal Insufficiency
    InterventionRivaroxaban
    PhaseNot recorded
    Registry statusUnknown

  • Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice

    NCT03847181 · start 2019-02-28

    Registered record
    Registry ID
    NCT03847181
    Conditions
    Atrial Fibrillation
    Interventions
    Rivaroxaban (Xarelto, BAY59-7939); Apixaban (Eliquis); Warfarin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-02-28
    Completion
    2020-10-31
    Enrolment
    45,164

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation
    InterventionRivaroxaban (Xarelto, BAY59-7939); Apixaban (Eliquis); Warfarin
    PhaseNot recorded
    Registry statusCompleted

  • Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACS

    NCT03775746 · start 2019-01-08

    Registered record
    Registry ID
    NCT03775746
    Conditions
    Acute Coronary Syndrome
    Interventions
    Clopidogrel 75Mg Tablet; Rivaroxaban 2.5Mg Tablet; Ticagrelor 90Mg Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-01-08
    Completion
    2021-12
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome
    InterventionClopidogrel 75Mg Tablet; Rivaroxaban 2.5Mg Tablet; Ticagrelor 90Mg Tablet
    PhasePhase 4
    Registry statusUnknown

  • Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion

    NCT03630055 · start 2018-10-03

    Registered record
    Registry ID
    NCT03630055
    Conditions
    Radial Artery Occlusion
    Interventions
    Rivaroxaban 15 MG Oral Tablet [Xarelto]
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2018-10-03
    Completion
    2025-06-26
    Enrolment
    930

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRadial Artery Occlusion
    InterventionRivaroxaban 15 MG Oral Tablet [Xarelto]
    PhasePhase 3
    Registry statusTerminated

  • Treatment Pattern of NOACs (Non-vitamin K Oral Anticoagulants) in Outpatient Users in Colombian Databases

    NCT03474757 · start 2018-02-28

    Registered record
    Registry ID
    NCT03474757
    Conditions
    Atrial Fibrillation
    Interventions
    Data Collection
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-02-28
    Completion
    2018-07-30
    Enrolment
    10,528

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation
    InterventionData Collection
    PhaseNot recorded
    Registry statusCompleted

  • DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation

    NCT02666742 · start 2017-02-16

    Registered record
    Registry ID
    NCT02666742
    Conditions
    Ventricular Tachycardia; Premature Ventricular Contraction; Stroke
    Interventions
    DOAC; Aspirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-02-16
    Completion
    2021-04-30
    Enrolment
    246

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentricular Tachycardia; Premature Ventricular Contraction; Stroke
    InterventionDOAC; Aspirin
    PhasePhase 4
    Registry statusCompleted

  • Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban

    NCT02975453 · start 2016-12-05

    Registered record
    Registry ID
    NCT02975453
    Conditions
    Atrial Fibrillation
    Interventions
    Rivaroxaban (Xarelto, BAY59-7939)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-12-05
    Completion
    2020-08-26
    Enrolment
    1,481

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation
    InterventionRivaroxaban (Xarelto, BAY59-7939)
    PhaseNot recorded
    Registry statusCompleted